1-5 of 5
Huy Van Nguyen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Ibrahim Aldoss, Ghayas C. Issa, Michael Thirman, John DiPersio, Martha Arellano, James S. Blachly, Gabriel N. Mannis, Alexander Perl, David S. Dickens, Christine M. McMahon, Elie Traer, C. Michel Zwaan, Carolyn Grove, Richard Stone, Paul J. Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan, Yu Gu, Rebecca G. Bagley, Kate Madigan, Soujanya Sunkaraneni, Huy Van Nguyen, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 2): LBA-5.
https://doi.org/10.1182/blood-2023-192042
Published: 2023
Journal Articles

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Andrius Zucenka, Ghayas C. Issa, Martha Arellano, Sajad Khazal, Nandita Khera, Wendy Stock, Branko Cuglievan, Yu Gu, Huy Van Nguyen, Angela R. Smith, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 4950.
https://doi.org/10.1182/blood-2023-189036
Published: 2023
Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Ibrahim Aldoss, Ghayas C. Issa, Michael J Thirman, John DiPersio, Martha Arellano, James S. Blachly, Gabriel Mannis, Alexander Perl, David Dickens, Christine M. McMahon, Elie Traer, C. Michel Zwaan, Carolyn Grove, Richard Stone, Paul J Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan, Yu Gu, Rebecca G Bagley, Kate Madigan, Soujanya Sunkaraneni, Huy Van Nguyen, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 2907.
https://doi.org/10.1182/blood-2023-189762
Published: 2023
Journal Articles

The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

Margaret V. Ragni, MD MPH, Pencho Georgiev, MD, Michael Desmond Creagh, Toshko Jelev Lissitchkov, MD, Steve K. Austin, BMedSci, MBBS, Charles Richard Morris Hay, MDFRCP, FRCPath, Inga Hegemann, MD, Syed Rashid Saeed Kazmi, MBBS, Pratima Chowdary, MD, Savita Rangarajan, MBBS, MD, Meredith C. Foster, ScD, Qifeng Yu, PhD, Craig Benson, MD MS, Kate Madigan, MD, Huy Van Nguyen, PharmD, Shariq Ali, PhD, Ketaki Kadam, MS, Pallavi Jain, PharmD, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH
Journal: Blood
Blood (2018) 132 (Supplement 1): 2477.
https://doi.org/10.1182/blood-2018-99-112998
Published: 2018
Journal Articles

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Claude Negrier, MD, Margaret V. Ragni, MD MPH, Pencho Georgiev, MD, Toshko Jelev Lissitchkov, MD PhD, Huy Van Nguyen, PharmD, Kate Madigan, K John Pasi
Journal: Blood
Blood (2017) 130 (Supplement 1): 2366.
https://doi.org/10.1182/blood.V130.Suppl_1.2366.2366
Published: 2017